Company research
Ayala Pharmaceuticals, Inc.
CIK 1100397Updated Sep 24, 2026
SecurityADXS · NASDAQ · equity
Historical securities (1)
ADXSW · NASDAQ · warrant · closed Oct 19, 2018Name history
Advaxis, Inc. · through Jan 13, 2023GREAT EXPECTATIONS & ASSOCIATES INC · through Jan 5, 2005
ADXS price & chart
Loading TradingView…
NASDAQ:ADXS on TradingView ↗In the news
No coverage from other publishers is available.
Financials
FY 2023 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 16,579,000Source | 25,930,000Source | 46,780,000Source | 38,526,000Source |
| Property, Plant and Equipment, NetUSD | 540,000Source | 38,000Source | 118,000Source | 2,393,000Source |
| GoodwillUSD | 4,500,000Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 3,898,000Source | 110,000Source | 3,354,000Source | 3,261,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,882,000Source | 25,208,000Source | 41,614,000Source | 25,178,000Source |
| Assets, CurrentUSD | 7,528,000Source | 25,759,000Source | 43,257,000Source | 27,851,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,646,000Source | 551,000Source | 1,643,000Source | 865,000Source |
| Operating Lease, Right-of-Use AssetUSD | 102,000Source | 12,000Source | 40,000Source | 4,839,000Source |
| Other Assets, NoncurrentUSD | — | 11,000Source | 11,000Source | 182,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | — | 2,303,000Source | 7,892,000Source | 8,346,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 12,000Source | 2,000Source | 146,000Source | 78,000Source |
| Additional Paid in CapitalUSD | 172,797,000Source | 466,584,000Source | 467,342,000Source | 440,840,000Source |
| Retained Earnings (Accumulated Deficit)USD | -197,226,000Source | -442,959,000Source | -428,600,000Source | -410,738,000Source |
| Stockholders' Equity Attributable to ParentUSD | -24,417,000Source | 23,627,000Source | 38,888,000Source | 30,180,000Source |
| Liabilities and EquityUSD | 16,579,000Source | 25,930,000Source | 46,780,000Source | 38,526,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 25,018,000Source | 2,303,000Source | 7,880,000Source | 3,291,000Source |
| Operating Lease, Liability, CurrentUSD | 166,000Source | 12,000Source | 28,000Source | 962,000Source |
| Accounts Payable, CurrentUSD | — | 22,000Source | 87,000Source | 410,000Source |
| Operating Lease, Liability, NoncurrentUSD | 9,000Source | — | 12,000Source | 5,055,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | 2,150,000Source | 2,836,000Source | 1,737,000Source |
cash flow · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 369,000Source | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,223,000Source | 97,000Source | 566,000Source | 891,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -234,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -29,485,000Source | -15,284,000Source | -15,439,000Source | -21,940,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 5,946,000Source | -166,000Source | -11,000Source | -748,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | -37,000Source | — | — | — |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | 1,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 26,001,000Source | -956,000Source | 31,886,000Source | 15,503,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 2,488,000Source | -16,406,000Source | 16,436,000Source | -7,185,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 371,000Source | 50,000Source | 50,000Source | 50,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 26,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 500,000Source | 700,000Source |
| Amortization of Intangible AssetsUSD | 32,000Source | 233,000Source | 273,000Source | 337,000Source |
| DepreciationUSD | 334,000Source | 53,000Source | 387,000Source | 897,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | 4,853,000Source | 970,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 8,000Source | -1,439,000Source | — |
| Gain (Loss) on Termination of LeaseUSD | 238,000Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | 200,000Source | — | — | — |
| General and Administrative ExpenseUSD | 12,185,000Source | 8,891,000Source | 11,464,000Source | 11,090,000Source |
| GoodwillUSD | 4,500,000Source | — | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | 159,000Source | 94,000Source | 1,725,000Source |
| Income Tax Expense (Benefit)USD | -3,912,000Source | 50,000Source | 50,000Source | 50,000Source |
| Inventory Write-downUSD | 145,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -48,072,000Source | -14,359,000Source | -17,862,000Source | -26,469,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -48,072,000Source | -15,384,000Source | — | — |
| Nonoperating Income (Expense)USD | -15,718,000Source | — | — | — |
| Operating ExpensesUSD | — | 19,560,000Source | 22,026,000Source | 26,702,000Source |
| Other Nonoperating Income (Expense)USD | 28,000Source | -9,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | 28,115,000Source | 15,496,000Source |
income statement · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Total RevenueUSD | — | 250,000Source | 3,240,000Source | 253,000Source |
| Cost of RevenueUSD | 13,000Source | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -36,266,000Source | -19,310,000Source | -18,786,000Source | -26,449,000Source |
| Other Nonoperating Income (Expense)USD | 28,000Source | -9,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -51,984,000Source | -14,309,000Source | -17,812,000Source | -26,419,000Source |
| Income Tax Expense (Benefit)USD | -3,912,000Source | 50,000Source | 50,000Source | 50,000Source |
| Net Income (Loss) Attributable to ParentUSD | -48,072,000Source | -14,359,000Source | -17,862,000Source | -26,469,000Source |
| Earnings Per Share, BasicUSD per share | -7.99Source | -8.46Source | — | — |
| Earnings Per Share, DilutedUSD per share | -7.99Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 6,019,063Source | 1,818,639Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 6,019,063Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 32,000Source | 233,000Source | 273,000Source | 337,000Source |
| Current Income Tax Expense (Benefit)USD | -3,912,000Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | 200,000Source | — | — | — |
| General and Administrative ExpenseUSD | 12,185,000Source | 8,891,000Source | 11,464,000Source | 11,090,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -49,912,000Source | — | — | — |
| Interest Income, OtherUSD | — | 157,000Source | 5,000Source | 110,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -48,072,000Source | -15,384,000Source | — | — |
| Nonoperating Income (Expense)USD | -15,718,000Source | — | — | — |
| Operating ExpensesUSD | — | 19,560,000Source | 22,026,000Source | 26,702,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | 1,025,000Source | — | — |
| Research and Development ExpenseUSD | 24,081,000Source | 7,616,000Source | 10,562,000Source | 15,612,000Source |